Thus, we surmise that the effect of Yap1 inhibition may be mediated through a cancer cell–intrinsic, auto-/paracrine IL-11–dependent mechanism, which may potentially be augmented by a concomitant anti-tumor effect emanating from reduced IL-11 signalling in CD4 effector cells (42). The gene discussed is IL11; the disease is cancer.